Summary & Overview
HCPCS A9699: Radiopharmaceutical, Therapeutic, Not Otherwise Classified
HCPCS Level II code A9699 denotes a therapeutic radiopharmaceutical classified as “not otherwise classified,” used for administrations of radiopharmaceutical therapy that lack a dedicated HCPCS identifier. This code matters nationally as radiopharmaceutical therapies expand across oncology and specialty care, creating billing complexity and variation in payer policies. The designation signals novel or less common agents that may require case-by-case coverage and coding decisions.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise view of what A9699 represents clinically and administratively, plus coverage and coding context relevant to major national payers. The publication outlines common billing considerations, typical sites of service, and areas where variation or prior authorization often affects access.
This report provides benchmarks and policy context for therapeutic radiopharmaceuticals billed under A9699, notes common modifiers used in practice (where available), and highlights implications for service lines that deliver radiopharmaceutical therapy. Data not available in the input is explicitly noted where applicable.
Billing Code Overview
HCPCS Level II code A9699 is defined as Radiopharmaceutical, therapeutic, not otherwise classified. This code represents therapeutic radiopharmaceutical agents that do not have a more specific HCPCS Level II code assignment.
Service type: Therapeutic radiopharmaceutical administration
Typical site of service: Hospital outpatient departments, infusion centers, specialty clinics, or other settings where radiopharmaceutical therapies are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with metastatic neuroendocrine tumor or metastatic prostate cancer who is scheduled to receive a therapeutic radiopharmaceutical under the HCPCS Level II code A9699 (Radiopharmaceutical, therapeutic, not otherwise classified). The patient often presents to an outpatient nuclear medicine or radiation oncology infusion suite or to an inpatient oncology unit. Prior to administration, the multidisciplinary team—medical oncologist, nuclear medicine physician, or radiation oncologist—reviews prior imaging (PET/CT, SPECT), laboratory values (renal function, hematologic counts), and prior therapies. Patient consent and radiation safety counseling are completed; pre-medication and hydration protocols are instituted as indicated. The nuclear pharmacy prepares the radiopharmaceutical under sterile, radioactive handling procedures and documents lot number, activity, and decay-corrected dose. On the day of service, the administering physician documents indication, dose administered, route, and any immediate adverse reactions. Post-therapy radiation safety monitoring and follow-up imaging or laboratory monitoring are scheduled per protocol. Billing uses A9699 for therapeutic radiopharmaceuticals that do not have an assigned HCPCS Level II code, with applicable modifiers to indicate circumstances such as professional component, multiple procedures, or unusual services.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |